Varun Dhir

Varun Dhir

Auto-generated profile, based on publicly available information

Varun Dhir

Division of Clinical Immunology and Rheumatology, Department of Internal Medicine Postgraduate Institute of Medical Education and Research Chandigarh India

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
NANupoor Acharya
Nupoor Acharya
SSShefali Khanna Sharma
Shefali Khanna Sharma
DMDebashish Mishra
Debashish Mishra
SDSahajal Dhooria
Sahajal Dhooria
VDVarun Dhir
Varun Dhir
SJSanjay K. Jain
Sanjay K. Jain

1 January 2007 in Internal Medicine
Verified
Journal Article
Closed access
VDVarun Dhir
Varun Dhir
VAVivek Arya
Vivek Arya
IMIshwar Chandra Malav
Ishwar Chandra Malav
SBSuryanarayanan Bs
Suryanarayanan Bs
RGRajiva Gupta
Rajiva Gupta
ADA B Dey
A B Dey
'Idiopathic systemic capillary leak syndrome (SCLS), or Clarkson's disease is an unusual entity first described 45 years ago. It presents with recurrent episodes of shock due to leakage of the plasma, which is reflected by accompanying hemo-concentration, hypo-albuminemia and edema. We report the case of a young man with multiple episodes of shock with generalized edema and pleural effusion. An initial diagnosis of sepsis was made, but the lack of fever and absence of a demonstrable organism or source led to a revision of diagnosis to SLCS. The last review of this syndrome which analyzed 24 cases was published in 1990. Since then, 75 more cases have been reported. This article reviews these cases.

26 December 2020 in Arthritis & Rheumatology
Verified
Journal Article
Closed access
PDF file
ASAman Sharma
Aman Sharma
GNGsrsnk Naidu
Gsrsnk Naidu
VSVikas Sharma
Vikas Sharma
SJSaket Jha
Saket Jha
ADAaadhar Dhooria
Aaadhar Dhooria
PLPui Y Lee
Pui Y Lee

3 July 2009 in Lupus
Verified
Journal Article
Closed access
VDV Dhir
V Dhir
ASAP Singh
AP Singh
AAA Aggarwal
A Aggarwal
SNS Naik
S Naik
RMR Misra
R Misra
Apoptosis of lymphocytes is increased in patients with lupus. This may be pathogenic leading to increased load of autoantigens or may be a bystander effect of immune activation. A major unresolved issue is whether apoptosis is related to disease activity. Also its association with lymphocyte frequencies, anti-nucleosomal antibodies and serum IL 10 levels needs to be explored further. The aims of this study are to measure T- and B-lymphocyte apoptosis in patients with lupus and look at the effect of disease activity in a cross-sectional and longitudinal design and to determine frequency of T and B cells, level of anti-nucleosomal antibodies and serum IL 10 and assess their relationship with apoptosis. This study included 41 patients with SLE and 20 controls. A cutoff value of 4 in systemic lupus erythematosus disease activity index (SLEDAI) was used to separate active from inactive SLE. The frequency and degree of apoptosis of T and B lymphocyte were enumerated by flow cytometry using peripheral blood mononuclear cells (PBMCs) stained with CD3/CD19 and annexin V/PI. The data for T/B cell frequency are represented as % of these cells in the PBMC population, whereas percentage of apoptotic cells is out of total T or B cells. Serum anti-nucleosomal antibodies and IL 10 were assayed using ELISA. A repeat assessment of these parameters was carried out in 11 active patients when they became inactive. We found higher T-lymphocyte apoptosis in patients with SLE versus controls (14.8 ± 9.2, 7.2 ± 3.0; P < 0.05) and a lower frequency of T cells (72.7 ± 12.6, 79.9 ± 5.8; P < 0.05). T-lymphocyte apoptosis was higher in patients with active disease compared with inactive (18.5 ± 11.3, 11.6 ± 5.4; P = 0.05). Further, T-lymphocyte apoptosis directly correlated with SLEDAI (r = 0.37, P < 0.05) and inversely with T-cell frequency (r = −0.29, P < 0.05). Anti-nucleosomal antibodies correlated with SLEDAI but not apoptosis. On longitudinal follow-up, a decline in T-cell apoptosis was seen in patients with SLE, however this was not statistically significant. We confirmed a higher degree of apoptosis in T-lymphocytes in patients with SLE and found a direct correlation of T-cell apoptosis with disease activity. Patients had reduced T-cell frequency, which inversely correlated with T-cell apoptosis and may suggest a cause-effect relationship.

1 February 2012 in Clinical Reviews in Allergy & Immunology
Verified
Journal Article
Closed access
PDF file
VDVarun Dhir
Varun Dhir
AAAmita Aggarwal
Amita Aggarwal

1 October 2009 in Pharmacogenetics and Genomics
Verified
Journal Article
Closed access
SSShruti Sharma
Shruti Sharma
MDMitashree Das
Mitashree Das
AKAshok Kumar
Ashok Kumar
VMVishal Marwaha
Vishal Marwaha
SSSubramanian Shankar
Subramanian Shankar
BTBK Thelma
BK Thelma
Inter-individual variations to methotrexate (MTX) response among rheumatoid arthritis (RA) patients have been attributed to clinical heterogeneity and genetic variations influencing MTX pharmacology. In this study, we analyzed the association of polymorphisms in ATIC, AMPD1, ADA, and ADORA2A from the purine biosynthetic pathway with MTX response in RA patients from north India. We also assessed the cumulative contribution of these polymorphisms together with those from the receptor–metabolizer–transporter and folate pathway genes that we have previously investigated. RA patients recruited using the American College of Rheumatology criteria were grouped into good (n = 213) and poor (n = 68) responders to MTX, based on Disease Activity Score 28-3. Individual single nucleotide polymorphism association was tested using χ2 test, and cumulative contribution of all the single-nucleotide polymorphisms and cumulative contribution of all the SNPs and clinico-demographic factors were assessed using linear and logistic regression. G allele of ADA rs244076 [P = 0.02, odds ratio (95% confidence interval): OR (95% CI) = 1.66 (1.01–2.75)]; and T allele of ADORA2A rs5751876 [P = 0.04, OR (95% CI) = 1.55 (1.01–2.37)] were associated with poor response, but did not stand Bonferroni correction. On regression analyses, FPGS rs1544105, TYMS rs2853539, DHFR rs7387, and ADA rs244076 were identified as putative predictors for MTX response. Carriers of the FPGS rs1544105 AA and AG genotypes [OR (95% CI) = 3.47 (1.19–10.12)] and TYMS rs2853539 AA genotype [OR (95% CI) = 2.76 (1.50–5.07)] were predictors of poor response in our patient population. Genes from all the three pathways seem to contribute to MTX response in the Indian population. However, these observations need to be replicated in an independent sample set.